Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of alpha-gal syndrome, published as a randomized controlled trial.

Metabolic syndrome poses additional risk for postmenopausal women who are already at risk for osteoporosis.

The researchers hypothesized that a nutritional supplement containing anti-inflammatory phytochemicals and essential bone nutrients would produce a favorable bone biomarker profile in postmenopausal women with metabolic syndrome.

Who Took Part

The abstract describes 51 women taking part.

The age groups tagged for this paper are middle-aged adults, women only.

How the Study Was Run

In design terms this was a randomized, single-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Only one side, usually the women, was kept unaware of whether Vitamin D, K2, Magnesium and Zinc was given.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Anti-Inflammatory Agents, Berberine, Biomarkers, Bone and Bones, Cholecalciferol, Collagen Type I and Dietary Supplements.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 51 women in people with alpha-gal syndrome.

The publication is from 2011 (Nutrition research (New York, N.Y.)), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Alpha-gal syndrome research.